66 FR 147 pgs. 39498-39499 - Available for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Method and Compositions for Treating and Preventing Retinal Damage
Type: NOTICEVolume: 66Number: 147Pages: 39498 - 39499
FR document: [FR Doc. 01-18984 Filed 7-30-01; 8:45 am]
Agency: Defense Department
Sub Agency: Department of the Army
Official PDF Version: PDF Version
DEPARTMENT OF DEFENSE
Department of the Army
Available for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Method and Compositions for Treating and Preventing Retinal Damage
U.S. Army Medical Research and Material Command, DoD.
In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent Application No. 09/590,174 entitled "Method and Compositions for Treating and Preventing Retinal Damage" filed June 9, 2000. Foreign rights are also available (PCT/US00/15812). This patent has been assigned to the Untied States Government as represented by the Secretary of the Army.
Commander, U.S. Army Medical Research and Material Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702-5012.
FOR FURTHER INFORMATION CONTACT:
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Pual Mele, Office of Research Technology Assessment, (301) 619-6664. Both at telefax (301) 619-5034.
This invention relates to the use of dihydrolipoci acid and alpha-lipoic acid to treat and prevent retinal damage arising from physical forces such as laser beams and to compositions containing phenyl nitrones and dihydrolipoic acids or alpha-lipoic acid as neuroprotective agents. The protective effect is believed to be due to the metabolites ability to protect neurons by a direct antioxidant effect, recycling of antioxidant vitamins E and C by redox, enhancement of glutathione, creation of at least 8 species of free radicals, and enhancement of intracellular ATP. Such may be useful in glaucoma, temporal arteritis, macular degeneration, diabetic retinopathy, proliferative retinopathy, retinitis pigmentosa and as an adjunctive prophylactic therapy prior to or following cataract surgery.
Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 01-18984 Filed 7-30-01; 8:45 am]
BILLING CODE 3710-08-M